Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.

Autor: Plimack ER; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA. Electronic address: elizabeth.plimack@fccc.edu., Tangen C; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; SWOG Statistics and Data Management Center, Seattle, WA, USA., Plets M; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Kokate R; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA., Xiu J; Caris Life Sciences, Phoenix, AZ, USA., Nabhan C; Caris Life Sciences, Phoenix, AZ, USA., Ross EA; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA., Grundy E; Nationwide Children's Hospital, Columbus, OH, USA., Choi W; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA., Dinney CPN; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee IC; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fong M; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA., Scott Lucia M; University of Colorado School of Medicine, Aurora, CO, USA., Daneshmand S; Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Theodorescu D; Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA., Goldkorn A; Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA., Lerner SP; Baylor College of Medicine, Houston, TX, USA., Flaig TW; University of Colorado School of Medicine, Aurora, CO, USA., McConkey DJ; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
Jazyk: angličtina
Zdroj: European urology [Eur Urol] 2024 Oct; Vol. 86 (4), pp. 297-300. Date of Electronic Publication: 2024 Jul 14.
DOI: 10.1016/j.eururo.2024.06.018
Abstrakt: We previously reported that tumors harboring any one of four gene mutations (ATM, RB1, FANCC, or ERCC2) were likely to respond to neoadjuvant cisplatin-based chemotherapy (NAC), resulting in cancer-free surgical specimens at the time of cystectomy (pT0). Here, we report our validation of this finding. Using the CARIS 592 Gene Panel (Caris Life Sciences, Phoenix, AZ, USA), we analyzed 105 pre-NAC tumor specimens from a large multicenter trial (S1314) of either neoadjuvant gemcitabine and cisplatin (GC), or dose-dense methotrexate, vinblastine, Adriamycin, and cisplatin (DDMVAC). We found that a mutation in any one of these four genes predicted for pT0 at surgery (odds ratio = 5.36; 95% confidence interval [CI] 2.05, 14.02; two-sided p = 0.0006). The biomarker was better at predicting the presence of disease (negative predictive value for pT0 86%; 95% CI 73%, 94%) than the absence of disease (positive predictive value for pT0 48%; 95% CI 35%, 62%). There was no evidence of an interaction between the treatment arm (DDMVAC vs GC) and the genetic variant in terms of pT0. When combined with clinical assessment, these findings help inform patient selection for bladder preservation after cisplatin-based chemotherapy.
(Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: